疏肝葆胃汤联合PPI三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效观察

Clinical Effect Observation of Soothing Liver and Preserving Stomach Decoction Combined with PPI Triple Therapy in Treatment of Helicobacter Pylori Positive Peptic Ulcer

目的观察疏肝葆胃汤联合PPI三联疗法治疗幽门螺杆菌阳性消化性溃疡的临床疗效和安全性。方法选取2015年5月至2016年8月来我院就诊的幽门螺杆菌阳性消化性溃疡患者78例,随机分为实验组(n=39)和对照组(n=39),实验组在常规PPI三联疗法的基础上,加疏肝葆胃汤联合治疗,观察两组患者的治疗效果,患者接受治疗4周、2个月和3个月幽门螺杆菌的根除情况,以及出现的不良反应。结果实验组溃疡患者在接受疏肝葆胃汤联合PPI三联疗法治疗后,治疗效果显著好于接受常规治疗的对照组患者(P<0.05),3个月后实验组幽门螺杆菌根除情况(32例,82.05%)优于对照组(24例,61.54%),且两组患者均未出现明显的不良反应。结论疏肝葆胃汤联合PPI三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效显著,值得临床推广应用。

Objective To observe the liver remains a stomach soup combined PPI triple therapy in the treatment of helicobacter pylori positive peptic ulcer clinical efficacy and safety. Methods: in May 2015-August 2016 to our hospital 78 cases of patients with helicobacter pylori positive peptic ulcer, were randomly divided into experimental group(n=39) and control group(n=39), the experimental group in conventional PPI triple therapy on the basis of plus liver stomach soup combined treatment, to observe the therapeutic effect of two groups of patients, patients receiving treatment for 4 weeks, 2 months and 3 months of helicobacter pylori eradication, and the adverse reactions. Results: experimental ulcer patients undergoing liver remains a stomach soup combined PPI triple therapy after treatment, the treatment effect is significantly better than the control group treated with conventional treatment(P<0.05), the experimental group 3 months after helicobacter pylori eradication is superior to that in the control group(32 cases, 82.05%)(24 cases, 61.54%), and two groups of patients with no obvious adverse reaction occurred. Conclusion: liver remains a stomach soup combined PPI triple therapy in the treatment of helicobacter pylori positive peptic ulcer curative effect is distinct, worthy of clinical popularization and application.